No Data
News On BeiGene Ltd. (BGNE) Now Under ONC
BEIGENE has issued approximately 0.2565 million shares due to the return of restricted stock units.
BEIGENE (06160) announced that on December 31, 2024, approximately 0.2231 million shares will be issued due to the vesting of restricted stock units granted under the equity plan (excluding company Directors), and approximately 0.0334 million shares will be issued due to the vesting of restricted stock units granted to company Directors under the equity plan. A total of approximately 0.394 million shares will be issued from exercising stock options between December 1, 2024, and December 31, 2024.
Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene
The Hang Seng Index fluctuates around the 20,000-point mark, and short-term new stocks are seeing a return of profit-making effects ｜ A barometer of Hong Kong stocks.
① The Hang Seng Index is fluctuating around the 20,000 point mark, what hot topics is the market focusing on? ② The return of short-term new stock profitability effects, what impact does it have?
Open Source Securities: DLL3 is a star target with high expression in SCLC, and various domestic new drugs can be expected in the future.
DLL3 is highly expressed in 80% of SCLC patients, providing a better solution for targeted therapy. Currently, only one product targeting this point has been approved for market, resulting in a favorable competitive landscape.
BEIGENE (06160.HK) issued 0.1032 million shares due to the vesting of restricted stock units.
On December 30th, Gelonghui announced that BEIGENE (06160.HK) will issue 0.1032 million ordinary shares on December 29, 2024, due to the vesting of restricted stock units granted under the equity plan (excluding company directors).
No Data
